Bromocriptine

Manufactured by Bio-Techne

Sourced in United Kingdom

Bromocriptine is a laboratory reagent used in research applications. It is a dopamine receptor agonist that can be used to study the effects of dopamine signaling in various experimental systems.

Automatically generated - may contain errors

Lab products found in correlation

Sulpiride, by Merck Group (1 mentions) Quinpirole, by Bio-Techne (1 mentions) Buprenorphine hydrochloride, by Merck Group (1 mentions) Olmesartan, by Bio-Techne (1 mentions) Rimonabant hydrochloride, by Bio-Techne (1 mentions) Angiotensin 2, by Merck Group (1 mentions) Naloxone hydrochloride, by Bio-Techne (1 mentions) Rapamycin tlrl rap, by InvivoGen (1 mentions) Dynorphin b, by Bio-Techne (1 mentions) Wn552122, by Bio-Techne (1 mentions) Damgo, by Phoenix Pharmaceuticals (1 mentions) Dopamine hydrochloride, by Merck Group (1 mentions) Sumanirole, by Merck Group (1 mentions) Pd128907, by Bio-Techne (1 mentions) L 741 626, by Merck Group (1 mentions) Haloperidol, by Merck Group (1 mentions) Glyceraldehyde 3 phosphate dehydrogenase gapdh antibody, by Cell Signaling Technology (1 mentions) Sch23390, by Bio-Techne (1 mentions) Skf38393, by Abcam (1 mentions)

Close spelling variants of this product

Bromocriptine mesylate

6 protocols using bromocriptine

Bromocriptine Modulates Lactational Anestrus

Check if the same lab product or an alternative is used in the 5 most similar protocols

To investigate the role of prolactin in mediating the extended period of lactational anestrus following pup removal in mice, C57BL/6J wild-type mice had pups removed the morning of day 5 of lactation and were then injected with bromocriptine. A 10-mg/mL bromocriptine mesylate salt (Tocris Bioscience catalog No. 0427) stock solution was prepared by dissolving the bromocriptine salt in 100% ethanol and diluted 1:20 with saline before injection. Mice were injected with either bromocriptine (5 mg/kg, subcutaneously; Tocris Bioscience catalog No. 0427, n = 9) or vehicle (saline with ethanol at same concentration as bromocriptine-treated mice; subcutaneously, n = 9), twice daily (0900 hours and 1700 hours) for 3 days (total 5 injections) with the last injection occurring 30 minutes before serial blood sampling for LH measurement. Following this, vaginal cytology was monitored daily in all mice until estrus was seen, and mice were euthanized on the first diestrus following this estrus.

Hackwell E.C., Ladyman S.R., Brown R.S, & Grattan D.R. (2023). Mechanisms of Lactation-induced Infertility in Female Mice. Endocrinology, 164(5), bqad049.

+ Open protocol

+ Expand

Optimized Reagent Procurement for Research

Check if the same lab product or an alternative is used in the 5 most similar protocols

Dopamine hydrochloride (#H-8502), S-(-)3-PPP (#P-103), Terguride (#T-134), angiotensin II (#A9525), and buprenorphine hydrochloride (#B9275) were purchased from Sigma-Aldrich; sulpiride (#0895), quinpirole (#1061), bromocriptine (#0427), olmesartan (#4616), Dynorphin B (#3196), naloxone hydrochloride (#0599), WN552122 (#1038), and rimonabant hydrochloride (#0923) from Tocris; DAMGO (#024-10) from Phoenix Pharmaceuticals, and rapamycin (#tlrl-rap) from Invivogen and morphine sulfate (#M1167) from Spectrum Chemicals.

Hauge Pedersen M., Pham J., Mancebo H., Inoue A., Asher W.B, & Javitch J.A. (2021). A novel luminescence-based β-arrestin recruitment assay for unmodified receptors. The Journal of Biological Chemistry, 296, 100503.

+ Open protocol

+ Expand

Dopamine Receptor Modulation of Behavior

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

All drugs were administered i.p. except L-741,626 which was administered s.c. Rats were tested in 3 cohorts of n = 16 each. Cohort 1 (n = 16) received bromocriptine (D2/3 dopamine receptor agonist; Tocris Bioscience), which was prepared in 50:50 DMSO and 0.9% saline. Cohort 2 (n=16) received PD128907 (selective D3 receptor agonist; Tocris Bioscience), which was prepared in 0.9% saline. Cohort 3 (n=16) received L-741,626 (selective D2 receptor antagonist), SB-77011-A (selective D3 receptor antagonist) and Sumanirole (selective D2 receptor agonist). L-741,626 (Sigma-Aldrich) was prepared in 51.67% DMSO and 48.33% saline. SB-77011-A (Tocris Bioscience) was prepared in 50:50 DMSO and 0.9% saline. Sumanirole (Sigma-Aldrich) was prepared in 0.9% saline. The drug doses and timing of injections prior to testing were based on previous studies that used these drugs in comparable behavioral tasks (Fernando et al., 2011; Koffarnus et al., 2011 (link), Simon et al., 2011 (link); St Onge and Floresco 2009 (link))..

Blaes S.L., Orsini C.A., Mitchell M.R., Spurell M.S., Betzhold S.M., Vera K., Bizon J.L, & Setlow B. (2018). Monoaminergic modulation of decision making under risk of punishment in a rat model. Behavioural pharmacology, 29(8), 745-761.

+ Open protocol

+ Expand

Pharmacological Interventions in Primate Model

Check if the same lab product or an alternative is used in the 5 most similar protocols

Bromocriptine (TOCRIS, UK) was dissolved in sterile saline and dosed at 0.315 mg/kg, 0.625 mg/kg, and 1.25 mg/kg. Haloperidol (Sigma, Germany) was dissolved in sterile saline and dosed at 0.001 mg/kg, 0.01 mg/kg, and 0.05 mg/kg. Phencyclidine (PCP; Chemsky [Shanghai] International Co., Ltd.) was dosed at 0.3 mg/kg. Sterile saline was administered to the control group. Drug injections were performed i.m. after 30 min. Typically, the monkeys were injected with drugs, then allowed to recover for 14 days before the next drug treatment.

Huang H., Ya J., Wu Z., Wen C., Zheng S., Tian C., Ren H., Carlson S., Yu H., Chen F, & Wang J. (2016). Dose-Dependent Changes in Auditory Sensory Gating in the Prefrontal Cortex of the Cynomolgus Monkey. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research, 22, 1752-1760.

+ Open protocol

+ Expand

Bromocriptine and Busprione Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Bromocriptine and Busprione were purchased from Tocris Bioscience (Bristol, UK) as mesylate and hydrochloride salts respectively.

Liberante F.G., Pouryahya T., McMullin M.F., Zhang S.D, & Mills K.I. (2015). Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia. Oncotarget, 7(6), 6609-6619.

+ Open protocol

+ Expand

Signaling Pathways in Adipocyte Metabolism

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies against peroxisome proliferator-activated receptor gamma co-activator 1 alpha (PGC1A) and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB 202190 were purchased from Calbiochem. Phosphospecific p38 MAPK, total p38 MAPK and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibodies were obtained from Cell Signalling. TOMM20 antibodies were purchased from Abnova (Taipei, Taiwan). ATP synthase beta antibodies and the specific D1-like agonist SKF 38393 were from Abcam. Specific UCP1 and D1-like receptor antibodies were purchased from Chemicon International. Specific D2-like receptor antibodies and the specific D2-like antagonist raclopride were from Santa Cruz Biotechnology. The specific D1-like antagonist SCH 23390 and D2-like agonist bromocriptine were purchased from Tocris Bioscience (Bristol, UK). Secondary antibodies were from Life Technologies. Fatty acid-free bovine serum albumin (BSA) was from Serva (Heidelberg, Germany). All other materials were obtained from Sigma-Aldrich.

Kohlie R., Perwitz N., Resch J., Schmid S.M., Lehnert H., Klein J, & Iwen K.A. (2017). Dopamine directly increases mitochondrial mass and thermogenesis in brown adipocytes. Journal of molecular endocrinology, 58(2).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!